However, you read it, the News today that Dir have been given shares at 1p when the Market mid is 28p looks like something out of the book "They never told such a story, you dreamt it"

So just what performance does such largess reward, I wonder?

Ah yes, the sp has increased 10-fold, ah so.

PS Don't you believe it! DYOR.
-the sp is down about 20% - over 12months...
maybe new directors are required.... and there should be questions of the Remuneration Ctt

Final Results

FINANCIAL HIGHLIGHTS

· Revenues increased 56% to £51.4m(2011: £32.9m)

· Like-for-like1 revenue growth of 11.6%

· Adjusted EBITDA2 profit of £4.8m(2011: loss of £1.3m)

· Adjusted profit before tax3 of £2.2m (2011: loss of £2.7m)

· Loss before tax of £9.8m (2011: loss of £11.7m)

· Strong improvement in operating cash flow +£10.7m vs 2011



OPERATING HIGHLIGHTS

· IS Pharma operations rapidly integrated and UK commercial operations restructured

· Significant contribution post acquisition of worldwide rights to Kelo-cote®

· Multiple product launches undertaken by Invida in Asia

· Quintiles partnership brings major opportunity in Mexico

· Trading since year end is in line with the Board's expectations


http://www.moneyam.com/action/news/showArticle?id=4444135

Distribution agreement and Placing to raise ?9m


http://www.moneyam.com/action/news/showArticle?id=4455383

Sinclair IS Pharma builds on dermatology portfolio
By Michael Millar

Mon 01 Oct 2012

SPH - Sinclair Is Pharma

Latest Prices
Name Price %
Sinclair Is Pharma 28.50p +6.05%
Valeant Pharmaceuticals International $55.27 -0.58%

Pharmaceuticals & Biotechnology 9,822 +0.67%

LONDON (SHARECAST) - Sinclair IS Pharma said it had secured a long term distribution agreement for three dermatology products.

The 100 year deal with Valeant Pharmaceuticals will the see Sinclair making an upfront payment of €9.0m for the rights.

The company will make additional sales-based payments over the life of the distribution agreement.

Sinclair will be responsible for sales, marketing and distribution of the products in Western Europe with distribution expected to begin at the beginning of December 2012.

Chief Executive Chris Spooner said the deal extended Sinclair's dermatology portfolio and enabled it to further leverage the firm's existing sales and marketing infrastructure in the region.

The products together generated revenues of €9.1m (around £7.3m) in the year ended December 31st 2011.

Annualised EBITDA contribution after investment in selling and promotional costs is expected to exceed £2m.

The transaction will be funded through a placing to raise £9m through the issue of 32,142,858 new ordinary shares of 1p each in the Company at 28p per share.

This price marks a 4% premium to the closing price on September 28th.

The proceeds of the placing will be used to fund the up-front payment, as well as working capital and transaction costs, the firm said.

Analysts at Brewin Dolphin said the company's strategic aspiration to build a significant specialty pharmaceutical business had taken a further positive step.

"The move further strengthens Sinclair's aesthetic dermatology franchise," they

Gone up the runway this morning and taken off.

Heavy selling this aft

Just had a dabble here.

Preliminary results for the year ended 30 June 2014

Directorate Changes

Oriel Securities Buy 28.75 28.63 40.00 40.00 Reiterates

Jefferies International Buy 28.75 28.63 45.00 45.00 Retains

Investec Hold 28.75 28.63 34.00 - Reiterates

Canaccord Genuity Buy 28.75 28.63 44.00 44.00 Reiterates

N+1 Singer Buy 28.75 28.63 40.00 40.00 Retains

finnCap Buy 28.75 28.63 43.00 43.00 Retains

May 2018.... now ~17p about 12 Months ago it was slightly up on the sp suggested by a Poster, here. ( but that would not include any Rights / Consolidations.)... tbh I've not really followed this recently - I guess there has been no good news that came my way.